SGP SpyGlass Pharma, Inc.
XNAS
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
SGP
—
—
What changed
Recent filings, trades and moves- Nov 12 Reports earnings
Key stats
Related
About
- Industry (SIC)
- SURGICAL & MEDICAL INSTRUMENTS & APPARATUS (3841) · industry map
- Exchange
- XNAS
- Market Cap
- $1.3B
- Employees
- 65
- List Date
- 2026-02-06
- CIK
- 0001778922
- Next Earnings
- 2026-11-12
- EPS Forecast
- ($0.62)
- Headquarters
- Irvine, CA
- Homepage
- https://www.spyglasspharma.com
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '26 | Avg |
|---|---|---|
| Jan | -- | -- |
| Feb | 6.06% | 6.06% |
| Mar | -3.07% | -3.07% |
| Apr | -6.14% | -6.14% |
| May | -19.68% | -19.68% |
| Jun | 21.51% | 21.51% |
| Jul | 13.39% | 13.39% |
| Aug | 15.08% | 15.08% |
| Sep | -3.20% | -3.20% |
| Oct | 21.66% | 21.66% |
| Nov | 2.35%* | 2.35% |
| Dec | -- | -- |
| Total | 48.12% | 48.12% |
* Only 1 year(s) of data available.
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $31.14
SMA 50: $28.59
SMA 200: —
Current: $34.43
EMA 12: $33.69
EMA 26: $31.23
MACD: 2.4583 | Signal: 0.3463
BULLISH
ADX (14): 36.34
TREND
+DI: 36.06
−DI: 19.36
Momentum Oscillators
RSI (14): 61.61
NEUTRAL
Stoch %K: 68.02
Stoch %D: 80.27
Williams %R: -41.45
Volume & Volatility
BB Upper: $39.36
BB Lower: $22.93
NEUTRAL
OBV: 5,129,353
Vol SMA 20: 111,790
Vol ROC: -99.91%
ATR: $2.06
True Range: $0.25
HV 20: 68.2%
HV 30: 65.4%
HV 60: 55.1%
Data Summary
Data Points: 192
Last Updated:
Date Range: 2026-02-06T00:00:00 – 2026-11-10T00:00:00
AI Analysis
Written before SGP’s Aug 6 earnings report, so it doesn’t reflect the results.
Here is my comprehensive stock analysis report for SGP:
Executive Summary
BULLISH (Confidence level: 6/10) Key drivers: Trend reversal, momentum signals, and improving volatility regime. Primary risks: High beta, potential earnings miss, and mixed technical signals.
Investment thesis: SGP has been trending downwards due to high volatility, but recent momentum indicators suggest a potential trend reversal. We expect the stock to rebound in the short-term as volatility levels normalize.
Recent news sentiment impact: No recent news headlines are available, which may contribute to the market uncertainty and high volatility.
Technical Analysis
Trend Direction: Short-term (1-4 weeks): BEARISH, Medium-term (1-3 months): NEUTRAL, Long-term (3-12 months): BULLISH
Support/Resistance Levels: Key price levels from moving averages: $22.88 (SMA 20), $23.52 (SMA 50), and $26.15 (Upper Bollinger Band).
Momentum Signals: RSI interpretation: NEUTRAL (32.93) MACD signal: BEARISH Crossover Bollinger Bands position: MEAN REVERSION
Volume Analysis: Volume trends: INCREASING, institutional interest signals: MIXED
News & Sentiment Analysis
Recent Headlines Summary: No recent news headlines are available.
Sentiment Assessment: NEUTRAL sentiment due to lack of recent news.
Catalyst Identification: No upcoming earnings or significant events reported.
Market Narrative: The market narrative is uncertain, with no clear catalyst driving the stock price.
Risk & Volatility Assessment
Beta Interpretation: High risk relative to market (beta >1.5).
Volatility Regime: Current volatility levels are HIGH compared to historical averages.
Options Market Signals: IV Premium vs HV30: N/A (positive = implied richer than realized), unusual activity: NONE
Downside Protection: Support levels: $19.62 (Lower Bollinger Band) and $18.20 (previous low).
Market Context & Positioning
Sector Performance: SGP is underperforming the sector.
Institutional Activity: MIXED institutional interest signals.
Correlation Analysis: How stock moves relative to market (R-squared interpretation): 0.39, indicating a moderate correlation with the overall market.
Relative Valuation: Position within trading range: NEAR THE LOW END OF THE RANGE.
Key Levels & Action Items
Critical Price Levels: Support/resistance levels to monitor:
- $22.88 (SMA 20)
- $23.52 (SMA 50)
- $26.15 (Upper Bollinger Band)
- $19.62 (Lower Bollinger Band)
Breakout/Breakdown Levels: Technical levels that could trigger significant moves: $24.00, $25.50, and $18.20.
Time-Sensitive Catalysts: No upcoming earnings or significant events reported.
Risk Management: Stop-loss levels and position sizing considerations:
- Set a stop-loss at $19.62 to limit potential losses.
- Consider reducing position size due to high volatility and mixed signals.
Please let me know if this meets your requirements!
Generated
News
All SGP news →
SGP Options Activity & IV Rank
Loading options activity...
Spread Scanner
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Scanning bull put, bear call, iron condor and calendar spreads…
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
30 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Loading the implied volatility surface…
Volatility Smile
Loading the implied volatility smile…
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
Risk Metrics
Beta: 1.2385
Alpha: 38.06%
Correlation: 0.2846
R-Squared: 8.1%
Stock Volatility: 62.0%
Market Volatility: 14.3%
Analysis Details
Benchmark: SPY
Data Points: 192
Period: 252 trading days
Data Points: 192
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own SGP
1 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Millennium Management Hedge fund Izzy Englander | $11.3M | #1494 of 3716 | +8.2% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
SGP Institutional Ownership (13F)
Filings for 2026-06-30 · 20 already for 2026-09-30Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
SGP Insider Trading (Form 4)
Latest: 2026-02-11Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-02-11 | Bilal Arshad Khan | Director | Buy (P) | +135,000 | $16.00 | $2.16M | EDGAR |
| 2026-02-11 | Ali Behbahani | Director | Mixed Conv +6,454,801 · Buy +937,500 |
+7,392,301 | $16.00 | $15.00M | EDGAR |
| 2026-02-11 | Mohamad Makhzoumi | 10%+ Owner | Mixed Conv +6,454,801 · Buy +937,500 |
+7,392,301 | $16.00 | $15.00M | EDGAR |
| 2026-02-11 | Forest Baskett | 10%+ Owner | Mixed Conv +6,454,801 · Buy +937,500 |
+7,392,301 | $16.00 | $15.00M | EDGAR |
| 2026-02-11 | Paul Edward Walker | 10%+ Owner | Mixed Buy +937,500 · Conv +6,454,801 |
+7,392,301 | $16.00 | $15.00M | EDGAR |
| 2026-02-11 | Rajeev M. Shah | Director | Mixed Buy +3,690,000 · Conv +4,331,117 |
+8,021,117 | $16.00 | $59.04M | EDGAR |
| 2026-02-11 | Carmen Chang | 10%+ Owner | Mixed Conv +6,454,801 · Buy +937,500 |
+7,392,301 | $16.00 | $15.00M | EDGAR |
| 2026-02-11 | Rick Yang | 10%+ Owner | Mixed Buy +937,500 · Conv +5,097,538 |
+6,035,038 | $16.00 | $15.00M | EDGAR |
| 2026-02-11 | Anthony A. Florence Jr. | 10%+ Owner | Mixed Buy +937,500 · Conv +6,454,801 |
+7,392,301 | $16.00 | $15.00M | EDGAR |
| 2026-02-11 | Geoffrey B Pardo | Director | Mixed Buy +312,500 · Conv +1,875,013 |
+2,187,513 | $16.00 | $5.00M | EDGAR |
| 2026-02-11 | Edward T Mathers | 10%+ Owner | Mixed Conv +5,097,538 · Buy +937,500 |
+6,035,038 | $16.00 | $15.00M | EDGAR |
| 2026-02-11 | Kirk G. Nielsen | Director | Conv (C) | — | — | EDGAR | |
| 2026-02-11 | NEA 17 GP, LLC | 10%+ Owner | Mixed Conv +5,097,538 · Buy +937,500 |
+6,035,038 | $16.00 | $15.00M | EDGAR |
| 2026-02-11 | Scott D Sandell | 10%+ Owner | Mixed Conv +6,454,801 · Buy +937,500 |
+7,392,301 | $16.00 | $15.00M | EDGAR |
| 2026-02-10 | Kirk G. Nielsen | Director | Mixed Conv +3,145,619 · Buy +165,000 |
+3,310,619 | $16.00 | $2.64M | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
SGP Insider Holdings
15 insiders · @ $34.43
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Edward T Mathers | 10%+ Owner | 6,035,038 | $207.79M | $15.00M | 1 | 2026-02-11 |
| 2 | Carmen Chang | 10%+ Owner | 6,035,038 | $207.79M | $15.00M | 1 | 2026-02-11 |
| 3 | Scott D Sandell | 10%+ Owner | 5,097,538 | $175.51M | $15.00M | 1 | 2026-02-11 |
| 4 | Mohamad Makhzoumi | 10%+ Owner | 5,097,538 | $175.51M | $15.00M | 1 | 2026-02-11 |
| 5 | Kirk G. Nielsen | Director | 3,310,619 | $113.98M | $2.64M | 3 | 2026-02-11 |
| 6 | Vensana Capital I, L.P. | 10%+ Owner | 3,145,619 | $108.30M | $2.64M | 1 | 2026-02-10 |
| 7 | Forest Baskett | 10%+ Owner | 2,989,408 | $102.93M | $15.00M | 1 | 2026-02-11 |
| 8 | Anthony A. Florence Jr. | 10%+ Owner | 2,989,408 | $102.93M | $15.00M | 1 | 2026-02-11 |
| 9 | Ali Behbahani | Director | 2,989,408 | $102.93M | $15.00M | 2 | 2026-02-11 |
| 10 | NEA 17 GP, LLC | 10%+ Owner | 2,989,408 | $102.93M | $15.00M | 1 | 2026-02-11 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
SGP Board & Officers
As of SEC filings through Feb 11, 2026Directors 14
- Ali Behbahani · since Feb 5, 2026
- Bilal Arshad Khan · since Feb 5, 2026
- Elizabeth G. O'Farrell · since Feb 5, 2026
- Geoffrey B Pardo · since Feb 5, 2026
- Habib J Dable · since Feb 5, 2026
- Malik Y. Kahook · since Feb 5, 2026
- Michael Dybbs · since Feb 5, 2026
- Patrick H. Mooney · since Feb 5, 2026
- Peter Kolchinsky · since Feb 5, 2026
- RA Capital Healthcare Fund LP (entity) · since Feb 5, 2026
- RA Capital Nexus Fund III, L.P. (entity) · since Feb 5, 2026
- Ra Capital Management, L.p. (entity) · since Feb 5, 2026
- Rajeev M. Shah · since Feb 5, 2026
- Zachary Scheiner · since Feb 5, 2026
Officers 5
- Patrick H. Mooney · Chief Executive Officer · since Feb 5, 2026
- Malik Y. Kahook · President, Chief Medical Officer, Executive Chair · since Feb 5, 2026
- Jean-Frederic Viret · Chief Financial Officer · since Feb 5, 2026
- James Robert Dennewill Jr. · Chief Operating Officer · since Feb 5, 2026
- Chetan Pratap Pujara · Chief R&D Officer · since Feb 5, 2026
10% owners 16
- Ali Behbahani · since Feb 5, 2026
- Anthony A. Florence Jr. · since Feb 5, 2026
- Carmen Chang · since Feb 5, 2026
- Edward T Mathers · since Feb 5, 2026
- Forest Baskett · since Feb 5, 2026
- Mohamad Makhzoumi · since Feb 5, 2026
- NEA Partners 17, L.P. (entity) · since Feb 5, 2026
- Nea 17 Gp, LLC (entity) · since Feb 5, 2026
- New Enterprise Associates 17, L.P. (entity) · since Feb 5, 2026
- Paul Edward Walker · since Feb 5, 2026
- Peter Kolchinsky · since Feb 5, 2026
- RA Capital Healthcare Fund LP (entity) · since Feb 5, 2026
- Ra Capital Management, L.p. (entity) · since Feb 5, 2026
- Rajeev M. Shah · since Feb 5, 2026
- Rick Yang · since Feb 5, 2026
- Scott D Sandell · since Feb 5, 2026
Changes in the last 10 years (45)
| Feb 10, 2026 | Vensana Capital I, L.P. reported in an SEC filing no longer being a 10% owner |
| Feb 10, 2026 | Vensana Capital I GP, LLC reported in an SEC filing no longer being a 10% owner |
| Feb 10, 2026 | Peter Justin Klein reported in an SEC filing no longer being a 10% owner |
| Feb 10, 2026 | Kirk G. Nielsen reported in an SEC filing no longer being a director |
| Feb 10, 2026 | Kirk G. Nielsen reported in an SEC filing no longer being a 10% owner |
| Feb 5, 2026 | Zachary Scheiner became a director |
| Feb 5, 2026 | Vensana Capital I, L.P. became a 10% owner |
| Feb 5, 2026 | Vensana Capital I GP, LLC became a 10% owner |
| Feb 5, 2026 | Scott D Sandell became a 10% owner |
| Feb 5, 2026 | Rick Yang became a 10% owner |
| Feb 5, 2026 | Rajeev M. Shah became a director |
| Feb 5, 2026 | Rajeev M. Shah became a 10% owner |
| Feb 5, 2026 | Ra Capital Management, L.p. became a director |
| Feb 5, 2026 | Ra Capital Management, L.p. became a 10% owner |
| Feb 5, 2026 | RA Capital Nexus Fund III, L.P. became a director |
| Feb 5, 2026 | RA Capital Healthcare Fund LP became a director |
| Feb 5, 2026 | RA Capital Healthcare Fund LP became a 10% owner |
| Feb 5, 2026 | Peter Kolchinsky became a director |
| Feb 5, 2026 | Peter Kolchinsky became a 10% owner |
| Feb 5, 2026 | Peter Justin Klein became a 10% owner |
| Feb 5, 2026 | Paul Edward Walker became a 10% owner |
| Feb 5, 2026 | Patrick H. Mooney became a director |
| Feb 5, 2026 | Patrick H. Mooney became Chief Executive Officer |
| Feb 5, 2026 | New Enterprise Associates 17, L.P. became a 10% owner |
| Feb 5, 2026 | Nea 17 Gp, LLC became a 10% owner |
| Feb 5, 2026 | NEA Partners 17, L.P. became a 10% owner |
| Feb 5, 2026 | Mohamad Makhzoumi became a 10% owner |
| Feb 5, 2026 | Michael Dybbs became a director |
| Feb 5, 2026 | Malik Y. Kahook became a director |
| Feb 5, 2026 | Malik Y. Kahook became President, Chief Medical Officer, Executive Chair |
| Feb 5, 2026 | Kirk G. Nielsen became a director |
| Feb 5, 2026 | Kirk G. Nielsen became a 10% owner |
| Feb 5, 2026 | Jean-Frederic Viret became Chief Financial Officer |
| Feb 5, 2026 | James Robert Dennewill Jr. became Chief Operating Officer |
| Feb 5, 2026 | Habib J Dable became a director |
| Feb 5, 2026 | Geoffrey B Pardo became a director |
| Feb 5, 2026 | Forest Baskett became a 10% owner |
| Feb 5, 2026 | Elizabeth G. O'Farrell became a director |
| Feb 5, 2026 | Edward T Mathers became a 10% owner |
| Feb 5, 2026 | Chetan Pratap Pujara became Chief R&D Officer |
| Feb 5, 2026 | Carmen Chang became a 10% owner |
| Feb 5, 2026 | Bilal Arshad Khan became a director |
| Feb 5, 2026 | Anthony A. Florence Jr. became a 10% owner |
| Feb 5, 2026 | Ali Behbahani became a director |
| Feb 5, 2026 | Ali Behbahani became a 10% owner |
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
Recent SEC Filings
Latest: 2026-10-19
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
| Filing Date | Accession | Link |
|---|
Quarterly report — unaudited financials and MD&A. Filed 40–45 days after each of the first three fiscal quarters.
| Filing Date | Accession | Link |
|---|---|---|
| 2026-08-06 | 0001778922-26-000045 | EDGAR |
ETF Holders
48 ETFs hold SGP
25 shown · $418.55M total exposure · 0.03% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VXUS Vanguard Total International Stock ETF | Vanguard | 0.02% | $107.2M | — | 2026-09-30 |
| 2 | VEA Vanguard FTSE Developed Markets ETF | Vanguard | 0.02% | $70.4M | — | 2026-09-30 |
| 3 | IEFA iShares Core MSCI EAFE ETF | iShares (BlackRock) | 0.03% | $55.4M | $191.7B | 2026-11-09 |
| 4 | SCZ iShares MSCI EAFE Small-Cap ETF | iShares (BlackRock) | 0.21% | $27.0M | $12.9B | 2026-11-09 |
| 5 | VNQI Vanguard Global ex-U.S. Real Estate ETF | Vanguard | 0.73% | $26.2M | — | 2026-09-30 |
| 6 | REET iShares Global REIT ETF | iShares (BlackRock) | 0.41% | $20.2M | $4.9B | 2026-11-09 |
| 7 | VEU Vanguard FTSE All-World Ex-US ETF | Vanguard | 0.02% | $17.2M | — | 2026-09-30 |
| 8 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $14.6M | — | 2026-09-30 |
| 9 | SPDW State Street® SPDR® Portfolio Developed World ex-US ETF | SPDR (State Street) | 0.03% | $10.7M | $41.1B | 2026-11-09 |
| 10 | IXUS iShares Core MSCI Total International Stock ETF | iShares (BlackRock) | 0.02% | $10.2M | $57.6B | 2026-11-09 |
| 11 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.01% | $9.4M | $77.8B | 2026-11-09 |
| 12 | IDEV iShares Core MSCI International Developed Markets ETF | iShares (BlackRock) | 0.02% | $8.5M | $34.1B | 2026-11-09 |
| 13 | VPL Vanguard FTSE Pacific ETF | Vanguard | 0.06% | $7.6M | — | 2026-09-30 |
| 14 | IEMG iShares Core MSCI Emerging Markets ETF | iShares (BlackRock) | 0.00% | $6.6M | $144.9B | 2026-11-09 |
| 15 | VT Vanguard Total World Stock ETF | Vanguard | 0.01% | $6.3M | — | 2026-09-30 |
| 16 | INTF iShares International Equity Factor ETF | iShares (BlackRock) | 0.16% | $6.0M | $3.8B | 2026-11-09 |
| 17 | IWO iShares Russell 2000 Growth ETF | iShares (BlackRock) | 0.02% | $2.3M | $14.1B | 2026-11-09 |
| 18 | EPHE iShares MSCI Philippines ETF | iShares (BlackRock) | 1.57% | $2.2M | $142.5M | 2026-11-09 |
| 19 | IPAC iShares Core MSCI Pacific ETF | iShares (BlackRock) | 0.08% | $2.2M | $2.6B | 2026-11-09 |
| 20 | VXF Vanguard Extended Market ETF | Vanguard | 0.00% | $2.0M | — | 2026-09-30 |
| 21 | VSGX Vanguard ESG International Stock ETF | Vanguard | 0.03% | $1.6M | — | 2026-11-09 |
| 22 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.01% | $1.4M | — | 2026-09-30 |
| 23 | SCHA Schwab U.S. Small-Cap ETF | Nport | 0.01% | $1.2M | — | 2026-08-31 |
| 24 | IWN iShares Russell 2000 Value ETF | iShares (BlackRock) | 0.01% | $1.1M | $14.1B | 2026-11-09 |
| 25 | IWC iShares Micro-Cap ETF | iShares (BlackRock) | 0.09% | $1.1M | $1.2B | 2026-11-09 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
SGP vs Peers
Related companies, largest first| Company | Market cap | P/E | Revenue growth | YTD | IV rank |
|---|---|---|---|---|---|
| APGE Apogee Therapeutics, Inc. Common Stock | $10.2B | — | — | +78.2% | — |
| CRNX Crinetics Pharmaceuticals, Inc. | $9.0B | — | +2928.4% | +81.8% | — |
| SM SM Energy Company | $6.8B | 7.3 | +99.6% | +56.4% | 14 |
| CGON CG Oncology, Inc. Common stock | $6.7B | — | +666.0% | +75.2% | 100 |
| SGP SpyGlass Pharma, Inc. Common Stock | $1.3B | — | — | +30.4% | — |
| ICT ICT | — | — | — | — | — |
| BDO BDO | — | — | — | — | — |
| SMPH SMPH | — | — | — | — | — |
| BPI Grayscale Bitcoin Premium Income ETF | — | — | — | −26.2% | — |
| Peer median | $7.9B | 7.3 | +666.0% | +75.2% | 57 |
P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.